| Authors: |
Hannas BR; Eli Lilly & Company, Indianapolis, Indiana, USA., Bender SM; GSK, Collegeville, Pennsylvania, USA., Blasi E; Avidity Biosciences, San Diego, California, USA., Bowman CJ; Pfizer, Inc., Groton, Connecticut, USA., Cavagnaro JA; Access BIO, LC, Boyce, Virginia, USA., Chen CL; Health and Environmental Sciences Institute, Washington, District of Columbia, USA., Coder PS; Charles River Laboratories, Ashland, Ohio, USA., Duijndam B; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Hoberman A; Charles River Laboratories, Horsham, Pennsylvania, USA., Kim TW; Ionis Pharmaceuticals, Inc., Carlsbad, California, USA., Leconte I; Charles River Laboratories, Lyon, France., Maki K; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Matsumoto M; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Mikashima F; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Misner DL; Aligos Therapeutics, Inc., South San Francisco, California, USA., Mueller L; F. Hoffmann-La Roche, Basel, Switzerland., Powles-Glover N; Regulatory Science Associates, Largs, UK., Rayhon S; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, USA., Saffarini C; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Siezen C; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Sisler J; Eli Lilly & Company, Indianapolis, Indiana, USA., Wange RL; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., White T; Tacey White Toxicology Consulting, LLC, Philadelphia, Pennsylvania, USA., Templin MV; Charles River Laboratories, Reno, Nevada, USA. |
